Income before deduction of interest, taxes and amortization: Exicure, Inc. (XCUR)
Exicure, Inc. (XCUR) focuses on developing nucleic acid-based therapeutics, relying on grants and external capital. The operating cash flow reflects current trends, where 0.00 determines this specific parameter level. The company implements bioethical standards and sustainable laboratory practices. However, following restructuring, the business has stagnated at a low efficiency level while striving to minimize internal costs.
Summary analytical data breakdowns for Exicure (XCUR)
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- book capitalization information:
- business debt structure and liquidity details:
- earnings and market multiples details:
XCUR - Net Profit|Future Profit Exicure, Inc.|XCUR - Price to Earnings Ratio|Forward P/E Multiple Exicure Inc.|XCUR - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Exicure|XCUR - Operating profit EBITDA|Earnings per share for the last 12 months Exicure|XCUR - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months exicuretx.com|XCUR - Earnings growth in current year|Earnings growth forecast for next year Exicure, Inc.
Summary company analytics:XCUR - Exicure, Inc.
For the long-term investor, the reliability of Exicure, Inc. (XCUR) is determined by its ability to generate cash flow amidst volatile demand for nucleic acid delivery platforms. When analyzing the operating profit (EBIT) trend, one must consider the difference between revenue and direct costs, which allows for an assessment of the effectiveness of new licensing agreements and the overall resilience of the business to market shocks.
Competitor analysis for Exicure, Inc.
Operating profit EBITDA Tempus TEM|QGEN - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization IONS (ionispharma.com)|RGEN: Operating profit EBITDA|Profit before interest, taxes and amortization Avidity Biosciences Inc (RNA)|Operating profit before deduction of amortization CRSP|WGS: Income before deduction of interest, taxes and amortization|Operating profit EBITDA RARE|Operating income before deduction of amortization beamtx.com|Profit before payment of interest, taxes and amortization Sarepta SRPT|TWST: Operating profit before amortization|10x Genomics Corp - Operating profit EBITDA|Intellia Corp (NTLA) - Operating profit before deduction of amortization|STOK (Stoke Therapeutics) - Operating profit before deduction of amortization|BLFS - Operating income before deduction of amortization|Operating profit before deduction of amortization WVE|Operating profit before amortization MAZE (Maze Therapeutics, Inc.)|Operating profit EBITDA SION|Operating profit before deduction of amortization Prime Medicine Bio PRME|Taysha Gene Therapies - Operating profit before deduction of amortization|Operating profit EBITDA uniqure.com QURE|MGTX - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization RGNX (REGENXBIO Inc)|SLDB: Operating profit EBITDA|Operating profit before amortization OCGN|Profit before payment of interest, taxes and amortization Pacific Biosciences|Operating profit before amortization BNTC (benitec.com)|Operating profit EBITDA DSGN|Operating profit EBITDA Rocket Pharma (RCKT)|Operating profit EBITDA FDMT (4D Molecular Therapeutics Inc)|Lexeo Therapeutics Inc. (LXEO) - Profit before interest, taxes and amortization|KRRO: Operating profit before deduction of amortization|EDIT (editasmedicine.com) - Operating profit before amortization|SLN: Operating profit EBITDA|PRQR - Operating income before deduction of amortization|CDXS (Codexis Inc) - Operating profit EBITDA|Operating profit before deduction of amortization Sangamo BioSciences (SGMO)|Operating profit before deduction of amortization NAUT (Nautilus Biotechnology)|Operating profit EBITDA metagenomi.co (MGX)|Profit before payment of interest, taxes and amortization Precision BioSciences, Inc. DTIL|Income before deduction of interest, taxes and amortization GBIO|Boundless Bio, Inc - Operating profit EBITDA|Profit before interest, taxes and amortization Imunon, Inc.|PHIO (phiopharma.com) - Operating profit before deduction of amortization|Mustang Bio - Income before deduction of interest, taxes and amortization|RNAZ (TransCode Therapeutics Inc.) - Operating profit EBITDA|Bionano (BNGO) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Applied DNA (APDN)|bluebird bio, Inc - Operating profit before amortization|Operating profit EBITDA IPA (ImmunoPrecise Antibodies Ltd.)|OMGA - Operating profit before deduction of amortization|OMIC: Operating profit before deduction of amortization|Operating income before deduction of amortization Regulus Therapeutics, Inc. RGLS|SYRS (Syros) - Operating profit before deduction of amortization|Operating profit before amortization TBIO|TCON (TRACON Pharmaceuticals) - Operating profit EBITDA|Operating profit before deduction of amortization unitybiotechnology.com (UBX)
